질환 조절약 시장 규모, 점유율 및 성장 분석 : 치료 카테고리별, 치료 적응증별, 투여 경로별, 최종사용자별, 지역별 - 업계 예측(2026-2033년)

Global Disease-Modifying Agents Market size was valued at USD 61.2 Billion in 2024 and is poised to grow from USD 64.26 Billion in 2025 to USD 94.94 Billion by 2033, growing at a CAGR of 5.0% during the forecast period (2026-2033).

The market for global disease-modifying agents focuses on therapies that aim to slow or halt disease progression by targeting underlying pathological processes instead of merely alleviating symptoms. This sector is critical, as altering disease trajectories contributes to reduced long-term disability, lower healthcare expenses, and enhanced patient quality of life, thus boosting demand from payers and clinicians. Innovation has evolved from early disease-modifying antirheumatic drugs to sophisticated monoclonal antibodies and cell therapies. A significant driver of investment is translational science, linking molecular targets with sustained clinical results. The emergence of advanced biomarkers and precision medicine enhances patient stratification, improving trial success and attracting capital. Additionally, AI is transforming clinical development by streamlining discovery, patient selection, and protocol design, ultimately increasing the likelihood of successful outcomes.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Disease-Modifying Agents market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Disease-Modifying Agents Market Segments Analysis

Global disease-modifying agents market is segmented by therapy category, therapeutic indication, route of administration, end-user and region. Based on therapy category, the market is segmented into Biologic DMARDs, Conventional Synthetic DMARDs and Targeted Synthetic DMARDs. Based on therapeutic indication, the market is segmented into Rheumatoid Arthritis, Multiple Sclerosis (DMTs), Crohn's & Ulcerative Colitis and Psoriatic Arthritis & Ankylosing Spondylitis. Based on route of administration, the market is segmented into Oral Tablets, Subcutaneous Injection and Intravenous Infusion. Based on end-user, the market is segmented into Specialized Immunology Clinics, In-patient Hospital Units and Specialty Retail Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Disease-Modifying Agents Market

The Global Disease-Modifying Agents market is being propelled by significant advancements in biotechnological research and development in molecular biology and genetic engineering, which facilitate more precise targeting of disease pathways. This enhanced understanding of disease mechanisms, coupled with innovative platform technologies, empowers developers to create therapies that can modify disease progression rather than merely alleviate symptoms. Furthermore, the advancement of translational tools and biomarker identification streamlines clinical development processes and bolsters target validation, promoting collaboration and investment between industry and academic institutions. These developments pave the way for a robust pipeline of innovative agents, addressing unmet medical needs and boosting confidence in long-term therapeutic outcomes.

Restraints in the Global Disease-Modifying Agents Market

The Global Disease-Modifying Agents market faces several significant challenges that hinder the development and progression of candidates. The intricate nature of disease biology and complex scientific hurdles add layers of difficulty, slowing down the pace of innovation. Additionally, the uncertainty surrounding translational pathways and the variability in clinical manifestations complicate endpoint selection, making it harder to demonstrate proof of disease modification. This complexity leads to more resource-intensive and risky clinical development processes. Furthermore, specialized manufacturing and delivery requirements limit scalability, posing challenges for smaller developers. Collectively, these factors diminish investment interest and impede portfolio expansion, as stakeholders must navigate a host of scientific, regulatory, and operational obstacles before therapies can be made available to patients.

Market Trends of the Global Disease-Modifying Agents Market

The Global Disease-Modifying Agents market is experiencing a notable shift towards personalized therapeutic strategies, as the emphasis on patient stratification and individualized regimens gains traction. This trend drives the development of agents tailored to specific genetic, molecular, and phenotypic profiles, encouraging sponsors to adopt adaptive trial designs and biomarker-driven endpoints. Such strategies enhance clinical differentiation and perceived value while promoting collaboration among developers, diagnostic companies, and clinical centers. With payers and clinicians increasingly supportive of targeted approaches, the resulting clear benefit-risk profiles facilitate market access and long-term adoption for agents effectively altering disease progression.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Disease-Modifying Agents Market Size by Therapy Category & CAGR (2026-2033)

• Market Overview
• Biologic DMARDs
• Conventional Synthetic DMARDs
• Targeted Synthetic DMARDs

Global Disease-Modifying Agents Market Size by Therapeutic Indication & CAGR (2026-2033)

• Market Overview
• Rheumatoid Arthritis
• Multiple Sclerosis (DMTs)
• Crohn's & Ulcerative Colitis
• Psoriatic Arthritis & Ankylosing Spondylitis

Global Disease-Modifying Agents Market Size by Route of Administration & CAGR (2026-2033)

• Market Overview
• Oral Tablets
• Subcutaneous Injection
• Intravenous Infusion

Global Disease-Modifying Agents Market Size by End-User & CAGR (2026-2033)

• Market Overview
• Specialized Immunology Clinics
• In-patient Hospital Units
• Specialty Retail Pharmacies

Global Disease-Modifying Agents Market Size & CAGR (2026-2033)

• North America (Therapy Category, Therapeutic Indication, Route of Administration, End-User)
  • US
  • Canada
• Europe (Therapy Category, Therapeutic Indication, Route of Administration, End-User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Therapy Category, Therapeutic Indication, Route of Administration, End-User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Therapy Category, Therapeutic Indication, Route of Administration, End-User)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Therapy Category, Therapeutic Indication, Route of Administration, End-User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Amgen
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biogen
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GSK
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Regeneron Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Genentech
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Acorda Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Scripps Research
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• UCB
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Incyte Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vertex Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ionis Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations